GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
作者信息
Nava-Parada Pilar, Emens Leisha A
机构信息
The Johns Hopkins University and the Sidney Kimmel, Comprehensive Cancer Center Department of Oncology, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA.
出版信息
Curr Opin Mol Ther. 2007 Oct;9(5):490-7.
PMID:17932813
Abstract
GemVax AS, a subsidiary of Pharmexa A/S, is developing GV-1001, an injectable formulation of a promiscuous MHC class II peptide derived from the telomerase reverse transcriptase catalytic subunit (hTERT), for the potential treatment of solid tumors, including pancreatic, liver and NSCLC. GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer.
摘要
Zotero 插件